Chih-Yi Liao

4PUBLICATIONS
53CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Jul 23, 2026
Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial.

|Sep 30, 2025
Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations.

James J Harding, Do-Youn Oh, Teresa Macarulla Mercade

|Sep 14, 2024
Peptide Receptor Radionuclide Therapy versus Capecitabine/Temozolomide for the Treatment of Metastatic Pancreatic Neuroendocrine Tumors.

Rushabh Gujarathi, Joseph Tobias, Sara Abou Azar

|Aug 02, 2024
MEN1/DAXX/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy.

Rushabh Gujarathi, Sara Abou Azar, Joseph Tobias

Pageof 1

Frequent Collaborators

1 joint publications

Rushabh Gujarathi

1 joint publications

Sara Abou Azar

1 joint publications

James J Harding

1 joint publications

Do-Youn Oh